2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2 · Dec 24, 2024 · US
Inhibitors of CD40-TRAF6 interaction
US9750717B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9750717-B2 |
| Application number | US-201615019581-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 9, 2016 |
| Priority date | Aug 27, 2012 |
| Publication date | Sep 5, 2017 |
| Grant date | Sep 5, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical composition comprising a compound having a formula selected from the group consisting of or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent and/or excipient. 2. The composition, according to claim 1 , comprising a compound having Formula II, or a pharmaceutically acceptable salt thereof. 3. The composition, according to claim 1 , comprising a compound having Formula III, or a pharmaceutically acceptable salt thereof. 4. The composition, according to claim 1 , comprising a compound having Formula IV, or a pharmaceutically acceptable salt thereof. 5. The composition, according to claim 1 , comprising a compound having Formula V, or a pharmaceutically acceptable salt thereof. 6. The composition, according to claim 1 , comprising a compound having Formula VI, or a pharmaceutically acceptable salt thereof. 7. The composition, according to claim 1 , comprising a compound having Formula VIII, or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Drugs for dermatological disorders · CPC title
Drugs for skeletal disorders · CPC title
having nitrogen atoms of imino groups further bound to halogen atoms · CPC title
having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings · CPC title
Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9750717B2 cover?
- The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.
- Who is the assignee on this patent?
- Ludwig-Maximilians-Universitaet Muenchen, Maastricht Univ, Acad Ziekenhuis Maastricht, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/381. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).